Publication
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerLung Adenocarcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR Exon 20 Insertioncivic_curation1.00
- variantEGFR S768Icivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22895145
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR Exon 20 Insertion2 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | accepted | EID4650In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monot… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC | civic |
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID4646A 78 year old M former smoker with lung adenocarcinoma with no prior therapy was tested for mutation in EGFR exons 18 to 21 and had Exon 20 in frame insertion. He had a three month course of first gen… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC | civic |
| EGFR S768I1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | — | accepted | EID4273In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously trea… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC | civic |
| EGFR V769_D770insASV1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID4649A 72 year old F never smoker with bronchioloalveolar carcinoma who had previously undergone surgery was tested for mutation in EGFR exons 18 to 21 and had Exon 20 in frame insertion. She was given fir… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC | civic |